Nel ASA: Insider Buy Puts €75,000 Bet on Water Electrolysis Turnaround

Nel ASA chairman bought 100,000 shares after order backlog dropped 24%. Stock surged 86% in 2025, far above analyst targets, as new platform aims to cut costs.

The chairman of Nel ASA bought 100,000 shares in April, just days after the Norwegian hydrogen specialist reported a 24% drop in its order backlog. Arvid Moss paid an average of 2.2547 Norwegian kroner per share — roughly €75,000 at current rates — in a rare display of board-level conviction that contrasts sharply with the chorus of analyst sell ratings.

The stock has since rocketed higher. On Friday it traded at €0.36, a fresh year-to-date high that extends the monthly advance to 50.53% and the 2025 rally to 86.49%. The move has lifted the share price well above the average 12-month analyst target of 1.867 NOK (about €0.16), creating one of the widest gaps between market pricing and professional consensus in the hydrogen space.

A technical breakout that defies the fundamentals

Chartists point to a decisive break of the multi-year downtrend, with the stock surging through resistance at €0.24 and €0.28. The former ceiling around €0.279 has now flipped into a critical support level. As long as Nel holds above that zone, the breakout signal remains intact, with the next major obstacle sitting at €0.415 — roughly 15% above current levels.

The velocity of the move is also evident in the distance to the 200-day moving average, which has stretched to 71.10%. That kind of premium typically signals powerful momentum, but it also raises the risk of profit-taking.

Behind the chart fireworks, the operating picture tells a far more sober story. In the first quarter, Nel generated 148 million Norwegian kroner in customer-contract revenue, a 5% decline from the prior-year period. The EBITDA loss narrowed by 15 million NOK to minus 100 million, while the net loss per share improved to minus 0.08 NOK from minus 0.10 NOK a year earlier.

The real red flag remains order intake. New bookings came in at just 85 million NOK, dragging the backlog down to 1.113 billion NOK — a 24% contraction. Without fresh orders, the company is burning through its cash cushion, albeit from a comfortable 1.4 billion NOK at the end of March.

No buy ratings among nine analysts

The analyst community has turned uniformly cautious. Among the nine institutions covering Nel, not one recommends buying the stock; seven advise selling. The price targets range from 1.00 NOK to 4.20 NOK (the latter matching the recent year-high of about €0.36), with a mean of 1.867 NOK — roughly half the current market price.

Berenberg last month reiterated "Neutral" but slashed its target from 2.60 to 2.30 NOK. Citigroup went further, cutting its target from 2.70 to 2.40 NOK, citing valuation risk. The professional consensus is essentially saying the rally has run ahead of any improvement in the underlying business.

A new platform designed to slash costs

Management is betting the turnaround on a new pressurised alkaline electrolyser platform that launched commercially in May after more than eight years of development and full-scale testing at the Herøya facility. The company claims the platform can reduce system CAPEX by 40% to 60% compared with current market solutions, while cutting operating expenses by 10% to 20%.

Energy consumption is expected to fall below 50 kilowatt-hours per kilogram of hydrogen, and the physical footprint will shrink by 80%. That combination is aimed at modular, containerised projects between 2.5 and 50 megawatts — a segment where Nel can deliver standardised units in under twelve months, speeding up revenue recognition.

On the PEM side, the company plans to build a prototype stack for the next-generation platform in 2026, targeting roughly 70% lower stack costs.

The push for standardisation, however, comes at a price. Two older production lines have been idled, and Nel is reviewing their book values for potential write-downs.

July 15 will test the rally

The next major catalyst arrives on July 15, when Nel releases its half-year results. Investors will focus on order intake, cash burn, and any early commercial traction for the new alkaline platform. If the company fails to signal a pick-up in demand, the stock's 86% year-to-date gain will look increasingly like a speculative advance on future scale-up rather than a reflection of current reality.

Until then, the technical picture remains supportive, and the insider purchase adds a sliver of credibility to the rally. But with nine analysts looking the other way, Nel's comeback story still needs a lot more than a chairman's bet and a broken downtrend to justify the price.